Breaking Abstract Plenary Session News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Breaking abstract plenary session. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Breaking Abstract Plenary Session Today - Breaking & Trending Today

Nevro to Highlight New Clinical Evidence at the 2021 North American Neuromodulation Society (NANS) Virtual Meeting

Nevro is proud to continue our longstanding commitment to investing in the field of neuromodulation and expanding our growing body of clinical evidence, said D. Keith Grossman, Chairman, CEO and President of Nevro. We are excited for Dr. Petersen and Dr. Kapural to share the significant data from the SENZA-PDN and the SENZA-NSRBP trials at NANS, reflecting our commitment to helping physicians treat underserved patient populations suffering from debilitating chronic pain. Additionally, we are pleased the many clinical investigators studying HF10 will have the opportunity to present the results of numerous additional studies we are conducting globally.
Key amongst these presentations will be data for the SENZA-Painful Diabetic Neuropathy (PDN) randomized clinical trial (RCT) and a first look at results from the Non-Surgical Refractory Back Pain (NSRBP) RCT: ....

United States , Redwood City , Erika Petersen , Julie Dewey , D Keith Grossman , Leonardo Kapural , Exchange Commission , American Neuromodulation Society , Nevro Corp , Prnewswire Nevro Corp , Carolinas Pain Institute , Investor Relations Corp Communications , University Of Arkansas , Virtual Meeting , Painful Diabetic Neuropathy , Non Surgical Refractory Back Pain , Diabetic Neuropathy , Restorative Neurosurgery , Medical Sciences , Principal Investigator , Central Time , Breaking Abstract Plenary Session , Surgical Refractory Back Pain , Medical Director , Host Investor Briefing , Chief Medical Officer ,

Nevro Announces FDA Submission for HF10® Therapy in Patients with Painful Diabetic Neuropathy

Nevro Announces FDA Submission for HF10® Therapy in Patients with Painful Diabetic Neuropathy
SENZA-PDN Study is Largest Prospective, Multicenter, Randomized Clinical Trial of Spinal Cord Stimulation Conducted to Date
News provided by
Share this article
REDWOOD CITY, Calif., Dec. 28, 2020 /PRNewswire/
Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that the company has submitted a pre-market approval supplement to the U.S. Food and Drug Administration (FDA) to seek approval of its Senza® System for the treatment of chronic pain associated with Painful Diabetic Neuropathy (PDN). ....

United States , Redwood City , Erika Petersen , Julie Dewey , D Keith Grossman , American Neuromodulation Society , Nevro Corp , Drug Administration , Investor Relations Corp Communications , Exchange Commission , University Of Arkansas , Painful Diabetic Neuropathy , Principal Investigator , Restorative Neurosurgery , Medical Sciences , Senza System , Diabetic Neuropathy , Conventional Medical Management , Virtual Meeting , Central Time , Breaking Abstract Plenary Session , Senza Omnia , Looking Statements , Private Securities Litigation Reform Act , Quarterly Report , Investor Relations ,

Nevro to Host Virtual Investor Briefing at 2021 North American Neuromodulation Society (NANS) Virtual Conference

Nevro to Host Virtual Investor Briefing at 2021 North American Neuromodulation Society (NANS) Virtual Conference
Friday, January 15, 2021, at 4:00 pm Pacific Time / 6:00 pm Central Time
News provided by
Share this article
Share this article
REDWOOD CITY, Calif., Dec. 22, 2020 /PRNewswire/ Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced it will host and webcast a virtual investor briefing at the 2021 North American Neuromodulation Society (NANS) Virtual Conference on Friday, January 15, 2021, beginning at 4:00 pm PST / 6:00 pm CST. Nevro Chairman, CEO and President D. Keith Grossman will host the event and will provide a business update and answer questions from investors about the Company s latest developments. Nevro s Chief Medical Officer, David Caraway, MD, PhD, and Nevro s Chief Financial Officer, Rod MacLeod, will also participate in ....

United States , Redwood City , Julie Dewey , Erikaa Petersen , D Keith Grossman , Leonardo Kapural , Department Of Neurosurgery , American Neuromodulation Society , Nevro Corp , Wake Forest University , Investor Relations Corp Communications , University Of Arkansas , Virtual Conference , Chief Medical Officer , David Caraway , Chief Financial Officer , Rod Macleod , Painful Diabetic Neuropathy , Non Surgical Refractory Back Pain , Diabetic Neuropathy , Medical Sciences , Central Time , Breaking Abstract Plenary Session , Surgical Refractory Back Pain , Senza Omnia , Investor Relations ,